Disease progression in MS often involves many changes in the brain such as inflammation, damage to the myelin sheaths that surround nerve fibres, repair of the myelin and loss of the nerve fibres themselves. Usually these changes are “silent” – that is they do not directly lead to obvious symptoms or symptom improvement.
Treatments for MS currently reduce inflammation and activity of the immune system and the next generation of treatments are focusing on repairing some of the damage caused by the immune system in MS. However, a major problem in assessing treatments is the lack of tools sensitive enough to identify these “silent” changes. This can make it difficult to determine whether there has been any disease progression in a person with MS or indeed whether there has been disease improvement in response to a particular treatment.
This project aimed to develop a magnetic resonance imaging (MRI)-based analysis platform to monitor silent disease progression in people with MS, and track changes to lesions, nerve fibres and myelin over time and across different areas in the brain.
During 2019, Dr Wang’s team has worked to integrate artificial intelligence (AI) into the analysis of neuroimaging (MRI) for MS. In collaboration with computer scientists and clinicians, they have developed a series of AI tools that significantly improves the efficiency and accuracy of a range of conventional and advanced neuroimaging markers for MS. This work has been featured in the media, invited international talks, and has also led to several industry partnerships including NVIDIA, the tech giant leading the graphics processing computing technology.
This improved image analysis has allowed the team to define microstructural changes in the brain that are associated with brain shrinkage in MS, including changes in the brain’s “white matter” beyond the MS lesions, that otherwise appears normal.
These AI tools will be eventually used to produce an online “disease status report” for people with MS.
It is hoped this platform will provide a framework that can be implemented in clinical trials to help test new myelin repair therapies and ultimately in clinical practice to monitor disease progression and treatment response.
Dr Wang has also contributed to the design of the MSBase-XNAT imaging repository: the largest MS clinical imaging repository in the world for the broader research community. The project commenced its development phase in early 2020.
Updated 18 June 2020
Updated: 04 January, 2019
Laboratory research that investigates scientific theories behind the possible causes, disease progression, ways to diagnose and better treat MS.
Research that builds on fundamental scientific research to develop new therapies, medical procedures or diagnostics and advances it closer to the clinic.
Clinical research is the culmination of fundamental and translational research turning those research discoveries into treatments and interventions for people with MS.